{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-267243","form_type":"8-K","ticker":"ENGN","cik":"0001980845","company_name":"enGene Therapeutics Inc.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.497618+00:00","generated_at":"2026-06-09T05:02:49.896736+00:00","sec_items":["1.01","2.01","9.01","3.02","3.03","5.01","5.02","5.03","5.05","5.06"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"enGene closes business combination with SPAC Forbion European Acquisition Corp., becomes public on Nasdaq","bullets":["New enGene shares and warrants trade on Nasdaq under 'ENGN' and 'ENGNW' starting Nov 1, 2023.","Approximately 10.4 million FEAC Class A shares were redeemed in connection with the deal.","Post-combination, Forbion Growth (31.9%), Lumira Ventures (14.4%), and others are top shareholders.","Company retains enGene's focus on non-viral gene therapies for mucosal tissues, lead candidate EG-70 for NMIBC.","PIPE financing was consummated alongside the transaction (amount not disclosed in this filing)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-267243","json":"https://secwatch.observer/filing/0001193125-23-267243.json","markdown":"https://secwatch.observer/filing/0001193125-23-267243.md","text":"https://secwatch.observer/filing/0001193125-23-267243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/0001193125-23-267243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/d567304d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:02:49.896736+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4a7c3c93211b9d2accd5f183f337affec3c133f7","claim":"enGene Therapeutics Inc.: FEAC and New enGene ceased to be shell companies upon closing of business combination (effective 2023-10-31).","evidence_excerpt":"On October 31, 2023, as a result of the consummation of the Business Combination, each of FEAC and New enGene ceased to be a shell company.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/0001193125-23-267243-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"shell status"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"governance_change"},{"claim_id":"b1bb2400de25cd5b700d6293e8d46a29e07b56de","claim":"enGene Therapeutics Inc.: Adopted new Code of Business Conduct and Ethics on October 31, 2023 (effective 2023-10-31).","evidence_excerpt":"on October 31, 2023, New enGene’s board of directors approved and adopted a new Code of Business Conduct and Ethics","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1980845/000119312523267243/0001193125-23-267243-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"code of ethics"},{"label":"Effective","value":"2023-10-31"}],"fact_type":"governance_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}